Olmesartán/Amlodipino/Hidroclorotiazida Viso Farmacéutica (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/Hydrochlorothiazide is a fixed‑dose combination that acts on several pathways involved in blood‑pressure regulation.

• Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
• High‑risk cardiovascular patients: helps achieve target blood pressure to lower risk of stroke and myocardial infarction.
• Patients with fluid retention: adds diuretic effect to improve volume control alongside vasodilation and renin‑angiotensin blockade.

• The combination pairs an angiotensin‑II receptor blocker (olmesartan) that blocks AT1 receptors, a calcium‑channel blocker (amlodipine) that relaxes vascular smooth muscle, and a thiazide‑type diuretic (hydrochlorothiazide) that promotes renal sodium and water excretion. Together they lower systemic vascular resistance and plasma volume, producing an additive antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after the first doses.
• Flushing: transient warmth or redness.
• Fatigue: general tiredness.
• Increased urination: due to the diuretic component.

Serious or Rare Side Effects

• Angio‑edema: swelling of lips, tongue or airway.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Electrolyte disturbances: significant changes in potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: abnormal liver enzymes.
• Blood dyscrasias: rare blood‑cell abnormalities.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal impairment: adjust dose or avoid if severe.
• Hepatic disease: use with caution; monitor liver function.
• Electrolyte imbalance: check potassium and sodium levels regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed.
• Elderly patients: start at lower dose and titrate slowly.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Olmesartan/Amlodipine/Hydrochlorothiazide may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Potassium‑saving diuretics or supplements: risk of hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., clarithromycin): increase amlodipine levels.
• NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase serum lithium concentrations.
• Other antihypertensives: additive blood‑pressure lowering effect.
• Antidiabetic agents: may enhance glucose‑lowering effect.
• Alcohol: can increase dizziness and hypotension risk.